NovaBridge Biosciences announced it will host a virtual business update call on March 9, 2026, to review Phase 2a clinical data for VIS-101 in patients with wet age-related macular degeneration. VIS-101 is a bispecific, tetravalent dual VEGF-A/ANG-2 inhibitor being evaluated in a randomized, dose-ranging Phase 2a study for wet AMD, with potential applicability in diabetic macular edema and retinal vein occlusion. The Phase 2a results have not yet been presented and are scheduled to be reviewed during the March 9 call.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-086892), on March 03, 2026, and is solely responsible for the information contained therein.